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IA–IC in the online-only Data Supplement). No paravalvular or central
leakage was detected and LVEF was unaltered. Echocardiographic
image quality did not allow for adequate assessment with regard to
the mechanism of THV dysfunction. Contrast-enhanced multidetector
computed tomography (MDCT) was performed. The THV was well-
positioned and circular both at the ventricular and aortic rim. The pos-
terior THV cusp was thickened by a low-attenuation mass consistentAn 83-year old female with severe aortic stenosis (peak gradient
45 mm Hg; mean gradient 25 mm Hg; effective oriﬁce area [EOA]
0.8 cm2) and reduced left ventricular function (LVEF 15 – 20%)
underwent transfemoral transcatheter aortic valve implantation
(TAVI). The patient had a history of priormyocardial infarction, percuta-
neous coronary intervention (PCI), moderate renal insufﬁciency and ab-
dominal aortic aneurysm, indicating high surgical risk (Society of
Thoracic Surgeons score of 9.5%). The patient's treatment with aspirin
(75 mg/d) and clopidogrel (75 mg/d) due to recent PCI was not
discontinued prior to the procedure.
A 26-mm Edwards Sapien XT transcatheter heart valve (THV) was
implanted corresponding to a nominal oversizing of 15% relative to
MDCT annular area. Re-dilatation of the THVwas not performed. During
the procedure the patient was stabilized using extracorporeal cardio-
pulmonary support (CPS) and inotropic therapy. The CPS circuit was
heparin-coated and additionally 5000 IE of unfractionated heparin
was administered during the procedure.
On pre-discharge transthoracic echocardiography (TTE) the THVwas
well functioning (peak gradient 9 mm Hg; mean gradient 5 mm Hg;
EOA 1.6 cm2, trivial paravalvular leakage) and the low LVEF persisted.
The remaining hospitalization was uneventful, and the patient was
discharged on standard post-TAVI dual antiplatelet therapy with aspirin
(75 mg/d lifelong) and clopidogrel (75 mg/d for 12 months).
At routine 3 months follow-up the patient's symptoms had im-
proved fromNew York Heart Association functional class IV to II. Trans-
esophageal echocardiography and TTE showed normal transvalvular
gradient (peak gradient 13 mm Hg; mean gradient 8 mm Hg; EOAy, Aarhus University Hospital
rk. Fax: +45 78 45 22 60.
land Ltd. Open access under CC BY-NC1.5 cm2) but restricted motion of the posterior THV cusp (Movies
with thrombus (Fig. 1). Oral anticoagulation therapy with warfarin
was initiated in combination with ongoing clopidogrel treatment
while aspirinwas discontinued. Threemonths later, MDCT demonstrat-
ed normal THV cusps with dissolution of the thrombus (Fig. 2), and cor-
respondingly echocardiography showed normalized cuspmobility with
normal transvalvular gradient (peak gradient 13 mm Hg; mean gradi-
ent 6 mm Hg; EOA 1.2 cm2) (Movies IIA–IIC in the online-only Data
Supplement).
Even though THV thrombosis is rare with an estimated incidence of
1%, several case reports have described THV stenosis caused by throm-
bosis [1–4]. In these cases the diagnosis was mainly based on a high
transvalvular gradient on echocardiography, most often without direct
visualization of the thrombus. As demonstrated in the present case visu-
alization of thrombus by echocardiography may be limited due to
acoustic shadows and reverberations from the prosthetic valve. In con-
trast, MDCT offers superior spatial resolution and produces isotropic
data allowing 3-dimensional imaging assessment. It should be noted
that although echocardiography demonstrated restrictive cusp motion
therewas no evident THV stenosis. However, THV thrombosis could po-
tentially cause cerebrovascular embolization or affect long-term THV
durability, thus underlining that even subtle signs of THV dysfunction
should warrant further imaging. If only echocardiography was per-
formed, the restrictive cusp motion could falsely have been interpreted
as primary structural failure of the THV.
This patient developed early THV thrombosis despite receiving
unfractionated heparin during the procedure followed by dual anti-
platelet therapy as most commonly used [5]. The severely reduced
LVEF is likely to have contributed to induce a prothrombotic state.
The optimal antithrombotic/anticoagulation treatment after THV
still remains uncertain, and further studies are warranted. Moreover, it
is important to identify individual patient and procedural characteristics
that are likely to increase the risk of thrombosis after TAVI, and to test
whether such modiﬁers should result in individual modiﬁcation of the
antithrombotic/anticoagulation treatment.-ND license.
Fig. 2.Multidetector computed tomography after 3 months of oral anticoagulation therapy. Short-axis (A) and long-axis (B) views of the transcatheter heart valve demonstrating success-
ful dissolution of the thrombus.
Fig. 1.Multidetector computed tomography 3 months after transcatheter aortic valve implantation. Short-axis (A) and long-axis (B) views of the transcatheter heart valve demonstrating
low-attenuation mass on the posterior cusp consistent with thrombus (black arrows).
25N.C. Hansson et al. / IJC Heart & Vessels 2 (2014) 24–25In conclusion, this case emphasizes the role of MDCT in evaluating
the mechanism underlying THV dysfunction when not apparent from
echocardiography.
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